文献速递膀胱癌与上尿路尿路上皮癌

卡介苗复溶后72小时内保持临床相关活性:短缺时期的实践启示

Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage.
PubMed 文献 · Eur Urol Oncol · 2020-05-29

针对高危非肌层浸润性膀胱癌的卡介苗(BCG)反复短缺,研究评估复溶后BCG的活菌数(CFU)与体外细胞毒活性,发现至少8小时活性稳定,24小时虽下降但不低于减量至三分之一水平,72小时仍接近50%且细胞毒潜力未减,提示短缺时可拆分药瓶并延长使用窗口。

要点

  • BCG复溶后8小时内活菌数稳定,24小时下降但未低于三分之一剂量水平。
  • BCG复溶后72小时活菌数仍接近50%,体外细胞毒潜力未下降。
  • 短缺时可拆分药瓶并在复溶后至少8小时(甚至72小时)内使用。

核心结论

  • BCG复溶后72小时内仍保持临床相关活性,支持在短缺时拆分药瓶并延长使用窗口。

研究设计与样本

  • 研究评估BCG复溶后活菌数(CFU)及体外共培养模型(BCG与白细胞及BCG敏感细胞系RT4-V6)的细胞毒潜力。

主要发现

  • 复溶后8小时活菌数下降9.1%(批次1,p=0.3)和4.8%(批次2,p=0.2),活性保持稳定。
  • 24小时活菌数低于基线,但未降至减量至三分之一时的水平(批次1为67%,批次2为60%)。
  • 72小时活菌数仍接近50%,体外模型显示BCG细胞毒潜力未下降。

关键数值与推荐

  • 复溶后至少8小时(甚至72小时)内BCG活菌数不低于减量至三分之一剂量时的水平。

临床怎么用

  • 短缺时期可拆分BCG药瓶,复溶后至少8小时(甚至72小时)内使用,以治疗更多患者并减轻物流压力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There have been repeated supply shortages of bacillus Calmette-Guérin (BCG), the gold-standard immunotherapy for patients with high-grade non-muscle-invasive bladder cancer (NMIBC). Organizations have issued guidance on coping with this shortage, including administering split-dose BCG such that one vial may treat up to three patients. However, logistical implementation of this strategy in a real-world setting is hampered by the recommendation to use BCG within 2 h of reconstitution. We assessed BCG viability in terms of colony-forming units (CFUs) and demonstrated that viability remained constant for at least 8 h after reconstitution (decline at 8 h of 9.1% for lot 1 [p = 0.3] and 4.8% for lot 2 [p = 0.2]). While the viability at 24 h was lower, it did not drop to a level below that of reducing the BCG dose to one-third (67% for lot 1 and 60% for lot 2) and remained close to 50% for at least 72 h. An in vitro model using co-culture of BCG and leukocytes with a BCG-sensitive cell line (RT4-V6) demonstrated no decrease in the cytotoxic potential of BCG at 72 h. In times of shortage, BCG vials may be split and administered for up to at least 8 h (or even 72 h) after reconstitution, allowing more patients to benefit from BCG while placing less strain on the logistics of clinical practice. PATIENT SUMMARY: The current supply of and increased demand for bacillus Calmette-Guérin (BCG), used in the treatment of bladder cancer, have led to repeated BCG shortages. One way to address this is to provide a reduced BCG dose to allow more patients to be treated. In this study we found that BCG viability remains clinically relevant up to 72 h after reconstitution, thus allowing for more patients to be treated from a single vial.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Brooks N, Nagaraju S, Matulay J, et al. Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. Eur Urol Oncol. 2020. PMID: 32475716. doi:10.1016/j.euo.2020.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。